Treating Older Adults with Generalized Anxiety Disorder

Manage webcast
Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
By 2050 there will be over 150 million older adults with anxiety disorders globally. Symptoms include sleep disturbance, interference with daily activities and distress, which can lead to medical illness such as coronary heart disease, disability, and higher levels of health care utilization.

Attendees will learn:
- How anxiety disorders in older adults differ from the disorders in younger adults.
~ They can be more detrimental to health and cognition in older adults.
~ These disorders may be more treatment-resistant, requiring aggressive treatment such as the combination of medication and psychotherapy.
- Why late-life anxiety disorders are undetected and undertreated.
- The benefits of using antidepressants and Cognitive-Behavioral Therapy as safer alternatives to treatment for these disorders in older adults.

Webinar Speaker:
Eric Lenze, MD
Associate Professor, Department of Psychiatry, Washington University School of Medicine

Dr. Lenze completed medical school and psychiatry residency at Washington University School of Medicine. He trained in a geriatric psychiatry fellowship and a clinical research fellowship at University of Pittsburgh, then joined the faculty, as part of the Advanced Center for Interventions and Services Research in Late-life mood disorders. In 2007, he returned to Washington University to focus on treatment studies in late-life anxiety disorders and depression. He carries out clinical research in disabled rehabilitating elderly populations and runs a faculty practice treating late-life anxiety disorders and depression.

Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme4
Oct 27 2010
76 mins
Treating Older Adults with Generalized Anxiety Disorder
More from this community:

Medical Research

  • Live and recorded (509)
  • Upcoming (13)
  • Date
  • Rating
  • Views
  • Achieving your ADME/Tox testing goals requires experience, quality data, and proper alignment with regulatory guidance. Failure to meet these important requirements can put your drug discovery and pre-clinical goals at risk.
    This presentation will provide an informative overview of how you can advance and reach your pre-clinical drug discovery goals. It will discuss the importance of core contract research capabilities, including enzyme induction, enzyme inhibition, and transporter interaction. In addition, we will review new capabilities and opportunities including CYP induction and SLC transporter assay services – all designed to align with regulatory agency guidance documents.

    Speaker Bio:
    David Stresser is the Program Manager of Corning® Gentest℠ Contract Research Services at Corning Life Sciences since 2001, having held prior positions of Product Manager and Study Director since joining Corning in 1998. Prior to this, he was a post-doctoral associate in the laboratory of David Kupfer at the University of Massachusetts Medical School in Worcester, Massachusetts. He did his graduate work in the laboratory of David E. Williams at Oregon State University in Corvallis, Oregon receiving a Ph.D. in toxicology in 1994. Dr. Stresser has authored or co-authored 40 articles or book chapters in the field of drug metabolism and has been an invited speaker at various national and international meetings, pharmaceutical companies, and universities.
  • Presentation 1: Jason Causon, Senior Applications Specialist, Sciex

    Development of bioanalytical LC-MS methods for the detection of therapeutic peptides and the proteolytic fragments of larger proteins and antibodies is growing along with the increasing number of peptide and protein drugs entering clinical research and development. Development of these methods present challenges that are different to small molecule method development because of the multiple charge states possible for a given peptide, the abundance of product ion possibilities and the large number of proteolytic fragments possible from a protein digest. In addition to optimizing for sensitivity, on-column HPLC method development is time consuming for the same reasons. In this webinar we present an automated tuning and optimization workflow with on-column validation using DiscoveryQuantTM 3.0 software with the new ChromaTune feature to overcome some of these challenges and make the optimization of peptide MRM methods easier and less time consuming.

    Presentation 2: Remco van Soest, Product Manager, Sciex

    Electrospray Ionization efficiency increases at lower flow rates. In this Webinar we will discuss how microLC can help you improve sensitivity in sample limited applications in bio-analysis by LC-MS. In order to analyse the same volume of sample as is typically injected in a conventional LC-MS system, up to 50 µL, we have developed a microLC system that allows for fast on-line pre-concentration on a short trap column. Because of the higher flow rates that can be used for loading the sample on the trap-column, sample throughput is not affected by using microLC flow rates for the LC-MS analysis.
  • Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market: it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

    Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the worlds aging populations. In contrast, stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.

    Join us as we discuss these and other key topics.
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Computer Aided Synthetic Design: How ARChem Can Improve Your Efficiency and Creativity

    Are you looking for a better way to synthesize a target molecule?

    Have you hit a roadblock in the lab or need an extra burst of creative thinking?

    Join Orr Ravitz at 10:00 AM (EDT) on July 16th for an overview of the future of synthetic design and the software that can help improve your efficiency and creativity in the lab with ARChem.

    He will discuss how medicinal chemists, process chemists and material scientists use ARChem as an idea generator – a tool for route scouting, for brain storming sessions, for the daily synthesis planning and potentially provide an alternative that gets you to curated experimental pathways faster than exploring the literature.

    This webinar will cover:

    ◦The technology behind ARChem and real life case studies
    ◦How ARChem can improve your productivity and creativity in the lab
    ◦Future developments of our synthetic design software
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information about how patients, physicians and payers behave through the use of open source, social media and real world data. However, segmentation still lacks clear insight into why these stakeholders behave as they do – and therefore how best to change their behaviour.
    Working with behavioural change experts Hamell, this one hour live discussion will look at why current segmentation strategies are failing, and the importance of understanding what drives patient or customer behaviour. Using case studies, speakers will explore how segmenting by behavioural drivers can create advanced, effective strategies to change patient, customer and payer behaviour.
    This event will focus on three key areas:

    •The theory behind behavioural segmentation and how it challenges the status quo
    •Benefits of behavioural segmentation communication strategies and the problems answered by behavioural segmentation strategies
    •Behavioural segmentation in action: practical application of this approach
  • How to Prepare and What to Ask of Your Suppliers:

    In an effort to thwart fraudulent medical manufacturing practices, the European Commission published a Commission Recommendation (2013/473/EU) focusing on the assessment and auditing practices of notified bodies in the field of medical devices.
    A particular emphasis in this Recommendation has been placed on unannounced audits. Unannounced audits are additional assessments by notified bodies of manufacturers and/or their critical material suppliers. Auditors commissioned by the notified body will be able to arrive on site without giving the manufacturer prior notice and proceed with inspection. Over 5,000 unannounced audits are expected this year alone and come in addition to the initial surveillance or renewal audits of a three-year certification cycle.

    Now is the time to make sure you and your supplier’s quality and supply chain management systems are in place and you have full transparency. Join us for this informational webinar discussing this trending regulatory standard and learn about what you and your suppliers should be doing to proactively prepare.
  • Channel
  • Channel profile
  • GAD and Substance Abuse Recorded: Nov 23 2010 70 mins
    Dr. Susan Sonne, Associate Professor of Psychiatry and Pharmacy at the Medical University of South Carolina
    Substance use disorders commonly co-occur with anxiety disorders. Diagnosing anxiety disorders in the face of active substance use and withdrawal can be very challenging due to the significant symptom overlap. This symptom overlap often leads to delayed or inadequate treatment. When treating individuals with generalized anxiety disorder and a substance use disorder, benzodiazepines should be avoided. Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors are FDA-approved to treat GAD and are fairly safe in substance users. Other non-FDA approved medications will also be discussed.

    During this webinar, attendees will learn:

    -What symptoms of anxiety overlap with substance use and withdrawal

    - How to diagnose anxiety disorders in the face of substance use

    -Why substance abuse and anxiety disorders co-occur so frequently

    -How to treat individuals with anxiety disorders and comorbid substance abuse

    Dr. Susan Sonne is active in research and teaching as Associate Professor of Psychiatry and Pharmacy at the Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Clinical Neuroscience Division.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme6
  • GAD and Cormorbidity: Impact on Patient Health Recorded: Nov 9 2010 66 mins
    Dr. Naomi M. Simon, Associate Director of the Center for Anxiety and Traumatic Stress Disorders
    Generalized Anxiety Disorder (GAD) is common, chronic, and associated with substantial impairment in function and quality of life. GAD commonly occurs comorbid with mood disorders and anxiety disorders. GAD comorbidity has been clearly linked to additive worsening of outcomes and function in both Major Depressive Disorder and in Bipolar Disorder. This presentation will provide an update on current understandings about the incidence and nature of GAD and comorbid disorders, and their impact on patient health.

    During this webinar attendees will:

    1) Understand the overlap of Generalized Anxiety Disorder (GAD) with mood disorders

    2) Understand the impact of GAD comorbidity on severity of illness including suicidality, quality of life and functioning in individuals with GAD

    3) Learn about the need to address GAD and its comorbidities to optimally improve patient health

    Naomi Michele Simon, M.D., M.Sc.

    Dr. Naomi M. Simon is Associate Director of the Center for Anxiety and Traumatic Stress Disorders and Director of the recently established Complicated Grief Program at Massachusetts General Hospital, and is Associate Professor of Psychiatry, Harvard Medical School.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME5
  • Treating Older Adults with Generalized Anxiety Disorder Recorded: Oct 27 2010 76 mins
    Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
    By 2050 there will be over 150 million older adults with anxiety disorders globally. Symptoms include sleep disturbance, interference with daily activities and distress, which can lead to medical illness such as coronary heart disease, disability, and higher levels of health care utilization.

    Attendees will learn:
    - How anxiety disorders in older adults differ from the disorders in younger adults.
    ~ They can be more detrimental to health and cognition in older adults.
    ~ These disorders may be more treatment-resistant, requiring aggressive treatment such as the combination of medication and psychotherapy.
    - Why late-life anxiety disorders are undetected and undertreated.
    - The benefits of using antidepressants and Cognitive-Behavioral Therapy as safer alternatives to treatment for these disorders in older adults.

    Webinar Speaker:
    Eric Lenze, MD
    Associate Professor, Department of Psychiatry, Washington University School of Medicine

    Dr. Lenze completed medical school and psychiatry residency at Washington University School of Medicine. He trained in a geriatric psychiatry fellowship and a clinical research fellowship at University of Pittsburgh, then joined the faculty, as part of the Advanced Center for Interventions and Services Research in Late-life mood disorders. In 2007, he returned to Washington University to focus on treatment studies in late-life anxiety disorders and depression. He carries out clinical research in disabled rehabilitating elderly populations and runs a faculty practice treating late-life anxiety disorders and depression.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme4
  • Treating GAD in Primary Care Settings Recorded: Oct 13 2010 78 mins
    Larry Culpepper, MD, MPH Professor and Chairman, Department of Family Medicine, Boston University
    Attendees will:
    - recognize symptoms of Generalized Anxiety Disorder in primary care patients
    - use current pharmacological and psychotherapeutic treatments to develop a management plan
    - assess different treatments for comorbid GAD and refractory cases

    Webinar Speaker:
    Larry Culpepper, MD, MPH
    Professor of Family Medicine and Chairman, Department of Family Medicine, Boston University

    Dr. Culpepper has conducted federally funded studies of depression and anxiety, otitis media, and school-based and community interventions to improve pregnancy outcomes and to prevent teen pregnancies. He currently is the principal investigator of an AHRQ funded developmental center for patient safety research devoted to the study of problems affecting low income and minority vulnerable populations in ambulatory care settings, and co-investigator of the Primary Care Anxiety Project, a study of the course of anxiety disorders in primary care settings.

    Dr. Culpepper also is Chief of Family Practice at Boston Medical Center. He received his MD degree from Baylor College of Medicine and his MPH degree from Boston University.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme3
  • Psychosocial Treatments for Generalized Anxiety Disorder Recorded: Oct 8 2010 72 mins
    Douglas Mennin, PhD, Director of the Yale Anxiety and Mood Services Clinic
    Attendees will:
    - Discuss current evidence-based psychotherapeutic treatments for adults with generalized anxiety disorder.
    - Identify characteristics of generalized anxiety disorder.
    - Design a psychosocial treatment plan with patients with GAD.

    Webinar Speaker:
    Douglas Mennin, PhD
    Associate Professor of Psychology, Yale University and Director of the Yale Anxiety and Mood Services Clinic

    Dr. Mennin has focused his research program on understanding and treating chronic and reoccurring bouts of anxiety and mood disorders, particularly worry, stress, and depression. Our understanding of problems related to anxiety and depression has increased exponentially in the past twenty years. Advances in biological and behavioral technologies has helped us shine light on how everyday feelings such as fear and sadness can, in some individuals, translate into emotional disorder.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME2
  • Understanding & Treating Generalized Anxiety Disorder Recorded: Sep 21 2010 77 mins
    Mark Pollack, MD, Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
    Attendees will:
    - discuss the neurobiology of GAD
    - recognize symptoms and diagnose individuals with generalized anxiety disorder
    - plan evidence-based treatment for individuals with GAD and gad and comorbid disorders including depression, sleep disorders, cardiac illnesses and IBS.

    Webinar speaker:
    Mark Pollack, MD, Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
    Professor of Psychiatry, Harvard Medical School

    Dr. Pollack’s areas of clinical and research interest include the acute and long-term course, pathophysiology, and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME1
Anxiety disorders are real, serious & treatable
Anxiety disorders are real, serious & treatable

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Treating Older Adults with Generalized Anxiety Disorder
  • Live at: Oct 27 2010 5:00 pm
  • Presented by: Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
  • From:
Your email has been sent.
or close
You must be logged in to email this